, French Polynesia experienced the largest Zika virus (ZIKV) outbreak ever described before the emergence of ZIKV in the Americas in 2015. As arbovirus transfusion-transmitted (TT) infections have been previously reported, we hypothesized that transfusion of blood products could also transmit ZIKV.
ZIKV viremia up to 7.3 3 10 6 copies/mL has been reported in Yap and most of the infections were asymptomatic. 3, 4 French Polynesia is a French overseas territory located in the South Pacific: it is a high endemic area for dengue. Between October 2013 and March 2014, French Polynesia experienced the largest ZIKV outbreak ever reported before the emergence of ZIKV in the Americas in 2015, with an estimate of 30,000 (11.5% of the population) people who reported a symptomatic infection. 2 Before the French Polynesian outbreak, ZIKV was believed to cause only mild disease characterized mainly by fever, rash, joint pain, and conjunctivitis, and ZIKV was believed to be transmitted only by mosquitoes. During this outbreak, the first severe complications of ZIKV infections (GuillainBarr e syndromes) were described. 5 When ZIKV emerged in October 2013, dengue virus (DENV) was cocirculating. 6 The Centre de Transfusion Sanguine de Polyn esie Française (French Polynesian Blood Bank, located in Tahiti, the main French Polynesian island) is the only blood bank of French Polynesia; its annual activity is approximately 6300 blood donations and approximately 5300 red blood cell (RBC) and 350 platelet (PLT; PLT concentrates and apheresis) transfusions. At the time of the ZIKV outbreak, all RBCs and PLTs were locally produced and fresh-frozen plasma was imported from France.
Arbovirus transmission by blood transfusion has been already reported for West Nile virus (WNV), 7 DENV, 8 Ross
River virus, 9 and yellow fever vaccine virus. 10 We hypothesized that ZIKV had the potential to be transmitted by blood transfusion. We herein describe mitigation strategies implemented in French Polynesia to prevent ZIKV-transfusiontransmitted (TT) infections. Some measures were not specific to ZIKV and have been implemented previously to prevent TT-dengue in French Polynesia: predonation screening of blood donors (medical questionnaire and medical examination: donors with recent symptoms suggestive of ZIKV infection or recent "dengue-like syndrome" were deferred for a 30-day period after resolution of symptoms); postdonation information (a dedicated phone number was specifically created to allow donors to provide postdonation information and to report all clinical symptoms suggestive of ZIKV infection or diagnosis of ZIKV infection); discard of all blood products that were collected from a donor who reported postdonation symptoms of ZIKV infection or dengue-like syndrome or whose sera was ZIKV RNA reactive; 7-day quarantine for RBCs before distribution; inactivation of apheresis PLTs using amotosalen and ultraviolet (UV)A illumination (INTER-CEPT, Cerus Corp.); 11 and importation of plasma from
France. In this study we will focus on nucleic acid testing (NAT) of blood donations and recipient follow-up.
MATERIALS AND METHODS

NAT of blood donations
Blood donor sera were tested using a laboratory developed ZIKV NAT assay (commercial molecular diagnosis tests and licensed tests for blood donor testing were not available at that time). 12 The limit of detection of the assay was approximately 100 copies/mL. 12 Briefly, sera donor samples were tested in pools of 3, constitutive sera of ZIKV-reactive pools were tested individually as previously reported. 12 Some reactive ZIKV RNA-reactive sera were sequenced to confirm specificity of our ZIKV NAT, as previously reported. 6, 12 Blood donor sera were also tested for DENV using another laboratory developed assay. ZIKV NAT was performed routinely from January 13, 2014, to February 17, 2014. Sera collected from blood donors from November 27, 2014, to January 12, 2014, were tested retrospectively. ZIKV NAT was performed by the Institut Louis Malard e, a public health and research institute located in Tahiti, French Polynesia. ZIKV RNA loads in asymptomatic blood donors were retrospectively determined as previously reported.
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Posttransfusion follow-up
Patients transfused with reactive ZIKV RNA samples (transfused before implementation of routine NAT) were retrospectively contacted, clinical symptoms consistent with ZIKV infections were recorded, and posttransfusion blood samples were collected for specific immunoglobulin class G (IgG) antibody detection by the Institut Louis Malard e, using a protocol previously described. 14 
Posttransfusion follow-up
Thirty RBC units from donors who were retrospectively tested before prospective NAT implementation, and were RNA reactive, were transfused into 26 recipients who were traced. Six patients died without any relation to ZIKV infection. Eight patients were lost for follow-up (patients living in remote islands). Twelve patients were investigated (medical examination and detection of IgG antibodies against ZIKV). Results of the investigation are reported in Table 1 . Patients 3 and 12 receiving inactivated apheresis PLTs (Patients 4 and 2, respectively) collected from ZIKV RNAreactive blood donors remained asymptomatic and did not develop detectable IgG antibodies against ZIKV, and nine of 12 (75%) patients transfused with ZIKV RNA-reactive blood products did not develop ZIKV antibodies against ZIKV. None of these patients reported any clinical symptoms consistent with ZIKV infection within the 2 months posttransfusion.
DISCUSSION
Managing the French Polynesian ZIKV outbreak was challenging because in late 2013, very little was known on this emerging pathogen. Supplying our population with safe blood products without shortage was one of the challenges. At the beginning of the outbreak, the French Polynesian blood bank could only base its safety policy on predonation screening of blood donors (questionnaire and clinical examination), blood donation deferral, and postdonation follow-up. French Polynesia is a remote country and supplying our blood bank with blood products collected from foreign ZIKV-free areas was impossible, except for plasma. It was also impossible to collect blood products from French Polynesia ZIKV-free areas because all the French Polynesia archipelagoes were affected. Data available from the Yap outbreak suggested that most of the infections were asymptomatic, highlighting the risk of collecting blood from infected blood donors, as previously reported with DENV and WNV. 15 Then, according to the experience of WNV in the United States, 7 we implemented a laboratory developed NAT assay to detect asymptomatic ZIKV RNA-reactive blood donors. A first ZIKV NAT assay received investigational new drug authorization from the Food and Drug Administration (FDA) for US donor screening in late March 2016 and screening of Puerto Rico donations began in early April 2016. 16 After the detection of ZIKV RNA-reactive asymptomatic blood donors in French Polynesia, the European Center for Disease Prevention and Control issued recommendations to prevent ZIKV-TT infections in February 2014, especially deferred blood donors with a travel history in areas with ongoing circulation of ZIKV.
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ZIKV NAT was an effective measure once implemented to prevent transfusion of ZIKV RNA-reactive blood products in French Polynesia but it is difficult to evaluate the effectiveness of this measure to prevent ZIKV-TT infection, which is a rare event. However, there are some limitations in the implementation of a specific NAT in the context of emergence: this requires the outbreak to be reported, the circulating agent to be identified, and advanced molecular laboratory capacity that allows the in-house validation or the implementation of licensed test. In addition, the implementation of routine NAT for both ZIKV and DENV was inconvenient and expensive. 18 The rate of NAT-reactive donations in French Polynesia (2.8%) was higher than recently reported in Puerto Rico (0.8% over the period of April to July 2016 and 1.8% during the latest week of reporting). 19 As most of ZIKV infections were asymptomatic, clinical questionnaire and examination, deferral of blood donors, quarantine of blood product after collection, and postdonation information that detected only seven (16.7%) reactive ZIKV blood donors were not effective enough to prevent collection of infectious blood. However, the number of blood donors deferred for ZIKV infection was unknown because blood donors reporting symptoms suggestive of ZIKV infection or recent "dengue-like syndrome" within the past 30 days were not tested for ZIKV and DENV. We detected no ZIKV-TT infection during the French Polynesian outbreak. Although ZIKV-TT infections were not detected, transfusion of ZIKV RNA-reactive blood products was identified retrospectively; thus, ZIKV-TT cannot be excluded. In addition, in an arbovirus-endemic area, if a positive recipient is identified, mosquito-borne transmission must be considered as a possible cause of infection.
There are some limitations in our posttransfusion investigations: small sample size, loss of follow up, high rate of asymptomatic cases, possible lack of sensitivity and specificity of ZIKV NAT and antibody testing. However, ZIKV-TT infections have been recently demonstrated in Brazil after transfusion of PLT concentrate. 20, 21 PLT inactivation by amotosalen and UVA has been implemented in French Polynesia in 2010 to prevent dengue-TT. Because of its efficacy in preventing TT of close related arboviruses (DENV, WNV, chikungunya virus), 11, 22 we assumed that the process also inactivated ZIKV. The efficacy of amotosalen and UVA was subsequently demonstrated to inactivate ZIKV in plasma up to 6.57 log TCID 50 /mL and 10.25 log copies/mL. 13 However, it should be kept in mind that pathogen reduction methods have been approved for PLTs and plasma but not yet for RBCs. Nevertheless, preventive measures such as NAT and pathogen reduction remain expensive and difficult to implement in poorly resourced countries. 23 Despite the magnitude of the outbreak, the French Polynesian blood bank was always able to supply blood products. The measures implemented allowed us to continue local blood collection and to avoid blood product shortages. The number of blood products provided by our blood bank did not decrease during the outbreak (5768 in 2012, 6112 in 2013, 6349 in 2014).
Mitigation strategies implemented in French Polynesia are recommended by both the World Health Organization and the FDA to reduce the risk of ZIKV-TT infections. 24, 25 The FDA recommended testing all donations collected in the United States and territories with an investigational ZIKV NAT or implementation of pathogen reduction for PLTs and plasma and pathogen reduction of whole blood or RBCs if an FDA-approved pathogen reduction device becomes available. As recently confirmed by the spread of ZIKV in the Americas, the French Polynesia experience demonstrated that ZIKV was a new challenge for blood transfusion. 26 
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